Medicare National Coverage Determination for Tuberculosis Infection (LTBI) Testing

On January 31, 2024, more than 25 academic, medical, public health, and community-based organizations co-signed a formal request to the National Centers for Medicare and Medicaid Services (CMS) for a national coverage determination (NCD) regarding TB infection testing. The request was accepted, but after more than a year its review has not started.

Members of Congress, please contact CMS Administrator Dr. Oz and demand an immediate review of this national coverage determination request. Here's why:

- TB is an airborne disease but preventable through testing and early treatment of persons with LTBI. Treating LTBI costs \$500-\$1300 per person, but if left to progress to full TB disease, costs rise to \$25,000-\$1,000,000 per case, with drug-resistant cases the most expensive.
- While the US has been a low incidence setting for decades, the number of TB cases has troublingly increased every year since 2020, with 2024 levels the highest in over a decade.
- Nearly a quarter of new TB diagnoses in 2024 occurred among persons over the age of 65.
- Medicare recipients have risk factors such as diabetes, kidney disease, cancer, immunosuppression treatments - that increase the risk of LTBI and TB disease. For example, more than 30% of Medicare recipients over 67 years of age have diabetes.

People with LTBI, also known as TB infection, are not sick but have TB bacteria in their body.

More than 80% of TB cases in the US are a result of untreated—and usually undetected due to an absence of testing—TB infection that progresses to full TB disease.

Over 50% of those who develop TB disease are hospitalized and 1 in 10 will die.

- The lack of an NCD creates a financial barrier to recommended TB preventive care for Medicare recipients. This is the ONLY preventive service for an infectious disease that has never had an NCD. This may have downstream consequences for coverage by other payors.
- An estimated 15 million Americans in the Medicare population would be eligible for LTBI screening with the implementation of an NCD, per the US Preventive Service Task Force (USPSTF) recommendations.
- A 2022 study estimated that a one-time intervention of LTBI testing and treatment for the Medicare-eligible population who had at least one risk factor for TB would prevent nearly 11,000 people from developing TB disease and over 2500 deaths.

For more information on TB and the NCD request, contact: leadership@stoptbusa.org













